Human study evaluating effectiveness and safety of Curezyme-LAC on body fat level and related metabolism in obese adults

Amicogen0 个研究点目标入组 100 人开始时间: 待定最近更新: 2022年9月20日

适应症

试验速览

暂无简介。

•1) Subject who voluntarily agree to participate and signs informed consent form
•2) 40 = age(men and women) < 65
•3) 25kg/? = BMI < 33kg/?
•4) waist circumference = 90 cm (male), = 85 cm (female)
•5) Subject who can comply with diet and exercise guidelines during the arbitration period

•1) Subject who consistently took medications that affect body weight, lipids, blood sugar metabolism, immune and inflammatory reactions, and intestinal health within one month of the first visit or are likely to take them during the study period
•2) Subject who has consumed of dietary supplements or oriental medicine affect body weight, lipid, blood sugar metabolism, immune and inflammatory reactions within one month before the first visit
•3) Subject who constantly consumed foods (included health functional foods) related to affect Intestinal health before the first visit
•4) Subject with following disease: Uncontrolled Hypertension, Liver dysfunction, Renal dysfunction, et al.
•5) Participation in commercial obesity program or experience of calorie-restricted theraphy within three months before the first visit
•6) Subject who has had a weight change of more than 5% within three months before the first visit
•7) Subject with surgical experience (esophagogastroplasty, enterectomy, et al.) for weight loss
•8) Subject who constantly exercised high-intensity as usual
•9) Participation in other human study within 1 month before the first visit
•10) Pregnant and lactating women
•11) Subjects with hypersensitivity to test materials
•12) Any condition that the principal investigator believes may put the subjects at undue risk

发起方

Amicogen